Bayer Highlights Hemophilia Strategy As Newer Drugs Carry Pharma Unit In Q2
This article was originally published in The Pink Sheet Daily
Company will prioritize potential Kogenate successor Kovaltry for hemophilia A, and delay filing of BAY 94-9027.
You may also be interested in...
A cautious patient population with long memories could thwart the potential of new hemophilia A treatments, even as the market leaders promise Wall Street that switching patients will be no problem.
The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.